CD8A and melanoma: In the present study, weaimed to evaluate the peptide antigen Trp1-gp100 (Table S2; Figure S17) when conjugated to LFN (Figure S18), followed by translocation into DCs.We envisioned that the anti-XCR1 scFv-mPAC would facilitate DC maturationand recruit CD8+ T cells when compared with the unconjugatedantigens (Table S3; Figures S19, S20).We hypothesized the dual activity of the melanoma antigens would increasethe immunogenic response against B16–F10 tumors.